Epithelial Ovarian Cancer

Oncology
8
Pipeline Programs
10
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 9 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
1 program
1
CarboplatinPhase 21 trial
Active Trials
NCT01146795Completed32Est. Apr 2015
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
GimatecanPhase 21 trial
Active Trials
NCT04846842Unknown46Est. Jul 2023
Zai Lab
Zai LabCA - South SF
1 program
1
NiraparibPhase 21 trial
Active Trials
NCT05385068Unknown35Est. Sep 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
PazopanibPhase 1/2Small Molecule3 trials
Active Trials
NCT02208128Unknown4Est. Feb 2018
NCT01543802Terminated21Est. Oct 2016
NCT01238770Completed10Est. Oct 2015
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
27T51Phase 11 trial
Active Trials
NCT06469281Recruiting90Est. May 2030
Novartis
NovartisBASEL, Switzerland
1 program
1
HKT288Phase 11 trial
Active Trials
NCT02947152Terminated9Est. Sep 2017
IB
Instil BioDALLAS, TX
1 program
1
ITIL-306Phase 11 trial
Active Trials
NCT05397093Active Not RecruitingEst. Nov 2039
Pfizer
PfizerNEW YORK, NY
1 program
1
MEK162, MEK inhibitor; oralPhase 11 trial
Active Trials
NCT01649336Completed36Est. Mar 2016
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Genomic BRCA and Extensive ovArian Cancer TestingN/A1 trial
Active Trials
NCT04027868Completed1,500Est. Nov 2022
Sanofi
SanofiPARIS, France
1 program
Seprafilm™N/A1 trial
Active Trials
NCT01095367Terminated15Est. Jan 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Zai LabNiraparib
Lee's PharmaceuticalGimatecan
Heidelberg PharmaPazopanib
GenentechCarboplatin
Heidelberg PharmaPazopanib
Regeneron27T51
Instil BioITIL-306
NovartisHKT288
PfizerMEK162, MEK inhibitor; oral
AstraZenecaGenomic BRCA and Extensive ovArian Cancer Testing
Heidelberg PharmaPazopanib
SanofiSeprafilm™

Clinical Trials (12)

Total enrollment: 1,798 patients across 12 trials

NCT05385068Zai LabNiraparib

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

Start: Jun 2022Est. completion: Sep 202435 patients
Phase 2Unknown
NCT04846842Lee's PharmaceuticalGimatecan

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Start: Jul 2021Est. completion: Jul 202346 patients
Phase 2Unknown
NCT01543802Heidelberg PharmaPazopanib

Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

Start: Apr 2013Est. completion: Oct 201621 patients
Phase 2Terminated
NCT01146795GenentechCarboplatin

Neoadjuvant Therapy for Ovarian Cancer

Start: May 2010Est. completion: Apr 201532 patients
Phase 2Completed
NCT01238770Heidelberg PharmaPazopanib

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Start: Nov 2010Est. completion: Oct 201510 patients
Phase 1/2Completed
NCT06469281Regeneron27T51

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Start: Aug 2024Est. completion: May 203090 patients
Phase 1Recruiting
NCT05397093Instil BioITIL-306

ITIL-306 in Advanced Solid Tumors

Start: Aug 2022Est. completion: Nov 2039
Phase 1Active Not Recruiting
NCT02947152NovartisHKT288

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Start: Dec 2016Est. completion: Sep 20179 patients
Phase 1Terminated
NCT01649336PfizerMEK162, MEK inhibitor; oral

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Start: Jul 2012Est. completion: Mar 201636 patients
Phase 1Completed
NCT04027868AstraZenecaGenomic BRCA and Extensive ovArian Cancer Testing

Genomic BRCA and Extensive ovArian Cancer Testing

Start: Dec 2019Est. completion: Nov 20221,500 patients
N/ACompleted
NCT02208128Heidelberg PharmaPazopanib

Molecular Determinants for Therapy Response on Renal Cell Carcinoma

Start: May 2014Est. completion: Feb 20184 patients
N/AUnknown
NCT01095367SanofiSeprafilm™

Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Start: Apr 2010Est. completion: Jan 201415 patients
N/ATerminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
23m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
23m ago

Office Administrator

SystImmune
23m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
34m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
37m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
37m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,798 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)